CN108753773A - Interfere CD19-CAR-T cells and its application of IFN-gama expression - Google Patents
Interfere CD19-CAR-T cells and its application of IFN-gama expression Download PDFInfo
- Publication number
- CN108753773A CN108753773A CN201810412693.3A CN201810412693A CN108753773A CN 108753773 A CN108753773 A CN 108753773A CN 201810412693 A CN201810412693 A CN 201810412693A CN 108753773 A CN108753773 A CN 108753773A
- Authority
- CN
- China
- Prior art keywords
- gama
- ifn
- shrna
- cells
- phr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses the shRNA of two kinds of interference people's IFN-gama gene expressions, such as SEQ ID NO:1, shown in 2.The invention also discloses a kind of Lentivirals, and it includes the shRNA for having interference people's IFN-gama gene expressions, and such as SEQ ID NO:The nucleotide fragments of encoding chimeric antigen receptor shown in 4.The invention also discloses a kind of CD19-CAR-T cells of interference people's IFN-gama gene expressions, to include the T lymphocytes of Lentiviral, or the T lymphocytes of the shRNA of interference people's IFN-gama gene expressions and the nucleotide fragments of encoding chimeric antigen receptor are integrated in chromosome.The CAR-T cells of the present invention introduce IFN-gama shRNA, and the shRNA of IFN-gama is co-expressed while expressing CAR, inhibit the release of IFN-gama from source by gene silent technology, to reduce the influence of CRS, improve the safety of CAR-T treatments.It is contemplated that preventing, treating preparing, having important application in the drug of adjuvant therapy of malignant tumor.
Description
Technical field
The present invention relates to the Chimeric antigen receptor T cell (Chimeric of the targeting CD19 of interference IFN-gama expression
Antigen Receptor Tcell, CAR-T) preparation and application, belong to genetic engineering and cell biology.
Background technology
1989, Chimeric antigen receptor transformation T cell (CAR-T) this concept was put forward for the first time, it is therefore an objective to establish tumour
The adoptive cellular therapy of specific recognition capability.The design of first generation CAR is simply to use monoclonal antibody specific source
ScFv (single-chain antibody variable region fragment) section replaces TCR (Tcell receptor)
Extracellular part, remain the regions CD3 ζ that transmembrane structure and intracellular transmit signal, some seminar's intracellular signal transfer parts
FcR can also be used by dividing.But the clinical test results of first generation CAR are very disappointing, a best clinical test of effect
Also only having 2/11 patient has long-term alleviation.As what is recognized immunology deepens continuously, it has been found that though CD3 ζ signals
So it is capable of the activation of inducing T cell and of short duration proliferation, but understands the incapability (anergy) of inducing T cell later.1998, there are two
Laboratory reports CD28 signal domains can provide the costimulation function of auxiliary for CD3 ζ signals.Therefore, second generation CAR
Design introduces the part of costimulatory molecules on the basis of the first generation, such as the intracellular signal structure of CD28 or CD137 (4-1BB)
Domain.And third generation CAR be then add the function signal structural domain of 2 costimulatory molecules, including CD27, CD28,4-1BB,
ICOS or OX40 (15-18).The mainly design of second generation CAR clinically tested now.
The effect of CAR-T, on August 30th, 2017, U.S. FDA had approved first CAR-T medicines recognized by the industry
Object --- Kymriah (tisagenlecleucel), for treating relapsed or stubborn (r/r) children and Young Adults B cell
Acute lymphoblastic leukemia.This is first granted immunocyte drug.October after one wheat harvesting period 18, FDA approvals
Kite pharmacy Yescarta (axicabtagene ciloleucel, KTE-C10), for treat to other therapies without response or
Person received the specific type recurred after at least two kinds of therapeutic schemes adult large B cell lymphoid tumor patient, including the big B of diffusivity is thin
Born of the same parents' lymthoma, transformant follicular lymphoma, primary mediastinal B-cell lymphoma.Yescarta is the 2nd section of CAR-T of FDA approvals
Therapy.
What is coexisted with the validity of CD-19-CAR-T therapies is its side effect and cytotoxicity.Due to being chosen when design
CD19 is target spot, and the T cell of input can kill itself existing normal B cells in vivo together with tumour cell, and swollen
After tumor disappears, normal B cells survival is not had as long as CAR-T cells still remain, in body, patient needs one timing of interval
Between injecting immune globulin to maintain basic humoral immunity.On the other hand, initial stage is inputted in CAR-T cells, due to T cell
Large amount of cell factor can be secreted in large amplification and T cell killing neoplastic process, patient will appear cytokine release synthesis
Disease (Cytokine Release Syndrome, CRS) is embodied in certain thin in fever, low blood pressure, anoxic and serum
The horizontal significant raising of intracellular cytokine, these factors include interferon-γ (IFN-gama), divide shape chemotactic factor (CF)
(Fracktalkine), grain-macrophage growth factor (GM-CSF), interleukin 5 (IL-5), interleukin-6
(IL-6), people's FMS-like tyrosine kinase 3 ligand (Flt-3L) and interleukin 10 (IL-10).At the beginning of 7 months 2016, general headquarters
It has issued and has been reported in the clinical test JCAR015 of the said firm's progress positioned at the Juno Therapeutics of Seattle, successively had
Death occurs after receiving CAR-T cell therapies for three patients's (being proved to be four afterwards), and FDA stopped JCAR015's immediately
Clinical test, it is because leading to neurotoxin using chemotherapeutics fludarabine, but also have many people to guess that Juno, which is then explained,
Being strong cellular factor storm (CRS) caused by the T cell due to input causes patient dead.Famous Novartis of Switzerland
(Novartis) although the products C LT019 of the targeting CD-19 of company can allow 80% conditions of patients to be eased, simultaneously
There is cytohormone release disease (CRS) in the patient for also resulting in nearly half.There is the patient's body of CRS, T cell can discharge excessively
Inflammatory factor, lead to too drastic inflammatory reaction and fever, it is serious if entail dangers to life.Likewise, California, USA
KitePharma companies are used to treat the product K TE-C19 of non Hodgkin lymphom, and 1/3 patient can be caused nerveous system occur
System side effect, 1/5 patient there is CRS, also two patients are dead in testing.
Usually, using large dosage of steroid hormone, such as prednisone, the clinical symptoms of CRS can be reversed rapidly.But
It is that steroid medicine can significantly inhibit the proliferation of CAR-T cells in vivo so that patient has higher recurrence rate, influences CAR-T
The effect for the treatment of.The blocking list that the preferable medicines of CRS are interleukin-6 receptors (IL-6R) is clinically handled now
Clonal antibody drug (Tocilizumab).Existing clinical test proves, can solve what CRS was brought rapidly after blocking IL-6 receptors
Toxic side effect and CAR-T cell proliferation in vivo is not influenced.Official approval Tocilizumab is used to treat FDA at present
In CAR-T therapies it is possible that CRS risks.But Tocilizumab is expensive, is no small economy for patient
Burden can largely mitigate CRS's if it is possible to cut off the release of IFN-gama cell factors from source
Risk, the safety of enhancing CAR-T treatments.
RNA interference (RNA interference, RNAi) be one kind is prevalent in organism, sequence-specific is strong,
The gene silencing mechanism of post-transcriptional level.Currently, using more universal performance interference effect small RNA molecular in animal body
Mainly there are siRNA (small interfering RNA), shRNA (short hairpin RNA) and amiRNA
(artificial microRNA) etc..It is earliest by external system using the method for gene function in RNAi technology research organism
The single-stranded siRNA molecule got ready is directly injected into nematode body, although being used in gene functional research later, this side
The interference timeliness of method is relatively short, and the concentration for improving siRNA to reach effectively interference often has cytotoxicity.Present
The method that RNAi technology uses is mostly to build a specific RNAi expression vector, can be by after the vector introduction animal and plant cells
Rna plymerase ii type or type III promoter transcription go out corresponding shRNA, amiRNA etc., and then interfere the expression of its target gene.
Currently, be commonly used to structure shRNA interference expression vectors method mainly have it is following two:(1) oligonucleotides moves back
Pyrogenic process, common practice are two specific Oligonucleolide primers of chemical synthesis, anneal to form both ends with glutinous in vitro
Property end double-strand shRNA segments, then connect conversion again with the carrier of cohesive terminus,cohesive termini with by digestion processing, contained
There is the recombinant plasmid of shRNA infection expression units.(2) PCR amplification method:Design pair for amplification control shRNA expression promoters
PCR primer, wherein forward primer are matched with promoter specificity, and 5 ' end of reverse primer is additionally plus for the dry of target gene
Target sequence is disturbed, PCR product is cloned on corresponding carrier, obtains shRNA interference expression vectors.
Interferon-gama (IFN-gama) is used as cytokine release syndrome (Cytokine Release
Syndrome, CRS) in the cell factor that plays a significant role, design passes through gene silencing skill for the shRNA of IFN-gama
Art inhibits the release of IFN-gama from source, to reduce the influence of CRS, is to improve CAR-T safeties, reduces toxic side effect
Beneficial to thinking.
Invention content
For the above-mentioned prior art, the present inventor passes through in-depth study and performing creative labour, successfully screens
2 kinds of shRNA that can interfere with IFN-gama gene expressions are gone out, and the shRNA and CD19CAR have been co-expressed.The hair of the present invention
A person of good sense has found, has co-expressed the CD19CAR-T cells of the shRNA of interference IFN-gama gene expressions, and killing expression CD19's is swollen
The burst size of the factors such as IL-6 during oncocyte, IFN-gama reduces, and to reduce the influence of CRS on source, carries
Safety in high CAR-T treatments.
The present invention is achieved by the following technical solutions:
The shRNA of people's IFN-gama gene expressions is interfered, there are two types of, it is respectively designated as IFN-gama shRNA-1, IFN-
The nucleotide sequence of gama shRNA-3, IFN-gama the shRNA-1 (sequence involved by the present invention, if without spy as follows
Do not mentionlet alone bright, be 5 ' -3 '), the nucleotide sequence of IFN-gama shRNA-3 is as follows.
IFN-gama shRNA-1 (such as SEQ ID NO:Shown in 1):
GCGGCCGCCGCAGAGCCAAATTGTCTCCTTTTCAAGAGAAAGGAGACAATTTGGCTCTGCTTTTT。
IFN-gama shRNA-3 (such as SEQ ID NO:Shown in 2):
GCGGCCGCCCATTCAGATGTAGCGGATAATTTCAAGAGAATTATCCGCTACATCTGAATGTTTTT。
In the sequence of IFN-gama shRNA-1, including for the siRNA of people's IFN-gama genes:
GCAGAGCCAAATTGTCTCCTT.In the sequence of IFN-gama shRNA-3, including for the siRNA of people's IFN-gama genes:
CATTCAGATGTAGCGGATAAT。
It is a kind of be used to prepare above-mentioned interference people IFN-gama gene expressions shRNA --- IFN-gama shRNA-1's draws
Object, nucleotide sequence (such as SEQ ID NO as follows:Shown in 5~8):
hIFN-gama-shRNA1-1st:GGCCGCCGCAGAGCCAAATTGTCTCCTTTTCAAGAGA;
hIFN-gama-shRNA1-2nd:AAGGAGACAATTTGGCTCTGCTTTTTGC;
hIFN-gama-shRNA1-3rd:AAGGAGACAATTTGGCTCTGCGGC;
hIFN-gama-shRNA1-4th:GGCCGCAAAAAGCAGAGCCAAATTGTCTCCTTTCTCTTGAA.
It is a kind of be used to prepare above-mentioned interference people IFN-gama gene expressions shRNA --- IFN-gama shRNA-3's draws
Object, nucleotide sequence (such as SEQ ID NO as follows:Shown in 9~12):
hIFN-gama-shRNA3-1st:GGCCGCCCATTCAGATGTAGCGGATAATTTCAAGAGA;
hIFN-gama-shRNA3-2nd:ATTATCCGCTACATCTGAATGTTTTTGC;
hIFN-gama-shRNA3-3rd:ATTATCCGCTACATCTGAATGGGC;
hIFN-gama-shRNA3-4th:GGCCGCAAAAACATTCAGATGTAGCGGATAATTCTCTTGAA.
The method that the shRNA of interference people's IFN-gama gene expressions is prepared using above-mentioned shRNA primers:Above-mentioned 4 are drawn
Object (is synthesized) dry powder rapid centrifugation by the Suzhou bio tech ltd Jin Weizhi, is diluted with water 100uM later, and 1st, 2nd,
3rd, 4th, respectively take 2.5ul, four total 10ul, moisturizing to 50ul to boil 5~10 minutes, be placed on natural cooling in pot and stay overnight extremely
Room temperature, by the process, four primers complete annealing, form section of DNA double-strand short-movie section.
A kind of Chimeric antigen receptor, including following cis- concatenated structural domain:Signal peptide, label gene, single-chain antibody, born of the same parents
Outer hinge area, transmembrane region and intracellular signal area, wherein single-chain antibody include light chain variable region (VL), heavy chain variable region (VH) with
And connect their hinge area.
The antigen that the single-chain antibody is identified be selected from CD19, CD20, CEA, GD2, CD22, CD23, CD30, CD33,
Any one or two kinds in CD44v7/8, CD70, VEGFR1, VEGFR2, IL-11R α, EGP-2, EGP-40, FBP, GD3 with
Upper (these antigens are existing in the prior art), preferably CD19, at this point, the amino of the light chain variable region of the single-chain antibody
Acid sequence is as follows, and the amino acid sequence of heavy chain variable region is as follows, and the amino acid sequence of hinge area is as follows.
The amino acid sequence of the light chain variable region of single-chain antibody:
KLISEEDLDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGT
DYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT。
The amino acid sequence of the heavy chain variable region of single-chain antibody:
EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQ
VFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS。
The amino acid sequence of the hinge area of single-chain antibody:GGGGSGGGGSGGGGS.
The amino acid sequence of the signal peptide is:MALPVTALLLPLALLLHAARPEQ.
The amino acid sequence of the label gene is:KLISEEDLTS.
In extracellular hinge area, the extracellular hinge area of CD28 or the extracellular hinge area of CD4 of the extracellular hinge area selected from CD8
Any one or two or more, the extracellular hinge area of preferably CD8;The amino acid sequence of the extracellular hinge area of the CD8 is:
TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI。
Any one in the transmembrane region of transmembrane region of the transmembrane region selected from CD8, the transmembrane region of CD28 or CD4 or two kinds
More than;It is preferred that CD8 transmembrane regions;The amino acid sequence of the CD8 transmembrane regions is:YIWAPLAGTCGVLLLSLVITLYC.
The intracellular signal area is selected from CD28, CD134/OX40, CD137/4-1BB, LCK, ICOS, DAP10, CD3 ζ and Fc
Any one in ε RI γ or two or more, preferably 4-1BB intracellular signals area and CD3 ζ intracellular signals area, or:CD28 intracellulars are believed
Number area and CD3 ζ intracellular signals area;The amino acid sequence in 4-1BB intracellular signals area and CD3 ζ intracellular signals area difference is as follows
It is shown.
The amino acid sequence in 4-1BB intracellular signals area:
SLKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE。
The amino acid sequence in CD3 ζ intracellular signals area:
LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRG。
Above-mentioned amino acid sequence is existing in the prior art.
Preferably, the Chimeric antigen receptor, amino acid sequence (such as SEQ ID NO as follows:Shown in 3).
SEQ ID NO:3:
MALPVTALLLPLALLLHAARPEQKLISEEDLDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKL
LIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSE
VKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQV
FLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCSLKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE
LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRG。
A kind of nucleotide fragments of the above-mentioned Chimeric antigen receptor of coding, nucleotide sequence (such as SEQ ID as follows
NO:Shown in 4).
SEQ ID NO:4:
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGCAGAAGCTGAT
CAGCGAGGAGGACCTGACTAGTGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAG
TCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTT
AAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGA
TTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGT
ACACGTTCGGAGGGGGGACCAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGA
TCTGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTC
AGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAA
TATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGC
CAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGG
TGGTAGCTATGCTATGGACTACTGGGGCCAAGGAACCTCAGTCACCGTCTCCTCAGGATCCACCACGACGCCAGCGC
CGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCG
GGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGG
GGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCTCCCTAAAACGGGGCAGAAAGAAACTCCTGTATATATTCA
AACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAA
GGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTA
TAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGG
GAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGT
GAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAA
GGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCGGCTAA。
A kind of Lentiviral, it includes the shRNA for having above-mentioned interference people IFN-gama gene expressions, shRNA tables
Up to frame, and (Lentiviral can express chimeric antigen to the nucleotide fragments of the above-mentioned Chimeric antigen receptor of coding simultaneously
Receptor and IFN-gama shRNA);The shRNA expression cassettes include that shRNA expresses promoter, and shRNA expression promoter is selected from
Any one in U6, H1 or 7SK, preferably U6;The nucleotide sequence of the U6 promoters is as follows.Slow virus expression carries
The construction method of body is conventional method.
The nucleotide sequence of U6 promoters:
AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGAT
AATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGT
AGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTG
GGTTTATATATCTTGTGGAAAGGACG。
Preferably, the structure of the Lentiviral is pHR-antiCD19CAR-U6-IFN-gama shRNA-1,
Or pHR-antiCD19CAR-U6-IFN-gama shRNA-3.
A kind of screening technique of shRNA, using pHR-IFN-gama-GFP and pHR-antiCD19CAR-U6-IFN-gama
The mode of shRNA plasmid co-transfections, by calcium phosphate transfection method, by CaCl2, two kinds of plasmids and water mix according to a certain percentage,
It is slowly dropped in the culture supernatant of 293FT cells, harvests 293FT cells afterwards for 24 hours, pass through RT-PCR and flow cytometer detection respectively
Method detects the expression of IL-6 in mRNA and protein level.
The slow virus carrier pHR-IFN-gama-GFP, it includes have the IFN-gama genes and GFP genes (can be same
When express IFN-gama and GFP).The IFN-gama genes, nucleotide sequence are as follows.The GFP genes, nucleosides
Acid sequence is as follows.
The nucleotide sequence of IFN-gama genes:
ATGAAGTACACCAGCTACATCCTGGCCTTTCAGCTGTGCATCGTGCTGGGCAGCCTGGGCTGCTACTGCCAGGACCC
CTACGTGAAGGAGGCCGAGAACCTGAAGAAGTACTTCAACGCCGGCCACAGCGACGTGGCCGACAACGGCACCCTGT
TCCTCGGCATCCTGAAGAACTGGAAGGAGGAGAGCGACAGGAAGATCATGCAGTCCCAGATCGTGAGCTTCTACTTC
AAGCTGTTCAAGAATTTCAAGGACGACCAGAGCATCCAGAAGAGCGTGGAGACCATCAAGGAGGACATGAACGTGAA
GTTTTTCAATAGCAACAAGAAGAAGAGGGACGACTTCGAGAAGCTGACCAACTACAGCGTGACCGACCTGAATGTGC
AGAGGAAGGCCATCCACGAACTGATCCAGGTGATGGCCGAGCTGAGCCCTGCCGCCAAGACCGGCAAGAGGAAGAGG
AGCCAGATGCTGTTCAGGGGCAGGAGGGCCAGCCAG。
The nucleotide sequence of GFP genes:
GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA
GTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCA
AGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC
ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCG
ACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCC
GACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGA
CCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCG
CCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTC
GGCATGGACGAGCTGTACAAG。
The method of the expression that IFN-gama is detected by RT-PCR methods is as follows:After harvesting 293FT cells, extraction is total
RNA(MiniBEST UniversalRNA,TAKARA,cat:9767), reverse transcription at cDNA (FastKing RT Kit, Tiangeng,
cat:KR11601), using the primer of IFN-gama, IFN-gama in mRNA level in-site is measured by the method for quantitative fluorescent PCR
It expresses (primer that reference gene β-actin need to be used).
The primer of the IFN-gama, including forward primer and reverse primer, nucleotide sequence are as follows:IFN-
gama-F:TCAGCTCTGCATCGTTTTGG;IFN-gama-R:GTTCCATTATCCGCTACATCTGAA.
The primer of the reference gene β-actin, nucleotide sequence are as follows:action-F:
CGCCCCAGGCACCAGGGC;action-R:GCTGGGGTGTTGAAGGT.
The method of the expression of the streaming method detection IFN-gama is as follows:After harvesting 293FT cells, the fluorescence of GFP is detected
Expression.
A kind of slow virus expression kit, including above-mentioned Lentiviral.
A method of utilizing above-mentioned Lentiviral Prepare restructuring slow virus:By the target gene of carrying
It is transfected into 293FT cells after Lentiviral, pCMV carriers and the mixing of pMD.2G carriers, 6~8h is changed to after transfection
Complete medium culture collects culture solution after 48h, and supernatant is retained after centrifugation and is filtered with 0.45 μm of filtering head, reservation filtrate, institute
State the solution that filtrate is recombinant slow virus.
A kind of CD19-CAR-T cells of interference IFN-gama expression, to include the T leaching of above-mentioned Lentiviral
The shRNA of interference people's IFN-gama gene expressions and the core of encoding chimeric antigen receptor are integrated in bar cell or chromosome
The T lymphocytes (IFN-gama shRNA and Chimeric antigen receptor can be expressed simultaneously) of acid fragments.The preparation of the recombination T cell
Method is conventional method.
The CD19-CAR-T cells of the interference IL-6 expression are pernicious in preparation prevention and/or treatment and/or auxiliary treatment
Application in the drug of tumour;Preferably, the malignant tumour is selected from acute lymphoblastic leukemia and/or chronic lymphocytic
Leukaemia.
The invention has the advantages that:
1. the present invention provides a kind of method that shRNA is inserted into expression vector, i.e., synthesize one section by 4 primer annealing methods
DNA double chain short-movie section.
2. the present invention provides a kind of effective ways of detection screening shRNA, i.e., by expressing IFN-gama shRNA's
The carrier pHR-IFN- of carrier pHR-antiCD19CAR-U6-IFN-gama shRNA and expression IFN-gama-GFP fusion proteins
The mode of gama-GFP cotransfections detects IFN-gama in mRNA and protein level respectively by the method for RT-PCR and streaming
The efficiency of shRNA gene silencings successfully filters out the shRNA of energy effective reticence IFN-gama gene expressions.
3. compared with existing antiCD19CAR-T cells, invention introduces IFN-gama shRNA, in expression CAR
While, the shRNA of IFN-gama is co-expressed, inhibits the release of IFN-gama from source by gene silent technology, to drop
The influence of low CRS improves the safety of CAR-T treatments.
4. compared with existing antiCD19CAR-T cells, pHR-antiCD19CAR-U6-IFN-gama shRNA-T are thin
Born of the same parents co-express the shRNA of IFN-gama while expressing CAR, the experimental results showed that, the shRNA of the IFN-gama of coexpression
IL-6 can be reduced, the generation of the release of the factors such as IFN-gama, control CRS side effects does not influence while increasing its safety
The expression of CAR does not influence the characteristic of its killing etc., exceeds the expectation of those skilled in the art.
Some essential terms involved in the present invention are described as follows;
Term " shRNA " (shorthairpinRNA), i.e. short hairpin RNA.ShRNA includes two short inverted repeats.
The shRNA being cloned into shRNA expression vectors includes two short inverted repeats, and centre is by a stem ring (loop) sequence separates
, hairpin structure is formed, is controlled by III promoters of pol.Then tanscription terminations of the 5-6 T as RNA polymerase III is connected again
Son.
Term " U6 promoters " is one kind in III promoters of pol, and position and base sequence are highly conserved, can be thin
Intracellular efficient transcription downstream structural sequence.It is the common promoters of shRNA.
Term " Chimeric antigen receptor " is artificial reconstructed receptor, can be by the specificity of tumor cell surface antigen point
Sub (such as antibody) is anchored on immunocyte (such as T cell), is made immunocyte identification tumour antigen or viral antigen and is killed swollen
Oncocyte or the cell of virus infection.
Term " single-chain antibody " (single-chain antibody variable region fragment, scFv) is
Finger is formed by antibody light chain variable region (areas VL) amino acid sequence and heavy chain variable region (areas VH) amino acid sequence through hinge connection,
With the antibody fragment for combining antigenic capacity.
Term " Linker " or hinge are the polypeptide fragments between the different albumen of connection or polypeptide, and the purpose is to make to be connected
Albumen or polypeptide keep respective space conformation, to maintain the function or activity of albumen or polypeptide.
Term " CD19 " refers to human leukocytes differentiation antigen 19, it NCBIGeneBank ID number be 930, have 2 it is different
Structure body (cDNA sequence/protein sequence), respectively NM_001178098.1/NP_001171569.1, NM_001770.5/NP_
001761.3.When referring to the amino acid sequence of CD19 comprising, the overall length of CD19 albumen or the CD19 with CD19 functions
Segment;It further include the fusion protein of the overall length or segment.Also, it will be appreciated by those skilled in the art that in the amino acid of CD19
In sequence, can it is naturally-produced or be artificially introduced mutation or variation (including but not limited to replacing, lack and or add), without shadow
Ring its biological function.Further include corresponding in its natural or artificial variants also, when describing the protein sequence fragments of CD19
Sequence fragment.
Description of the drawings
Fig. 1:IFN-gama shRNA and CD19CAR dual-expression vector structure charts.
Fig. 2:PHR-IFN-gama-GFP carrier mode figures.
Fig. 3:PHR-IFN-gama-GFP transfection efficiency streaming figures.
Fig. 4:PHR-antiCD19CAR-U6-IFN-gama shRNA transfection efficiency streaming figures.
Fig. 5:RT-PCR methods detection IFN-gama expression figures after cotransfection.
Fig. 6:Streaming method detection IFN-gama expression figures after cotransfection, wherein left figure is transfection efficiency streaming figure, and right figure is
Transfection efficiency bar chart.
Fig. 7:PHR-antiCD19CAR-U6-IFN-gama shRNA-T cell positive rate flow cytometer detection figures
Fig. 8:K562-CD19 monoclonal flow cytometer detection figures.
Fig. 9:The tumour that pHR-antiCD19CAR-U6-IFN-gama shRNA-T cell-specifics kill the CD19 positives is thin
Born of the same parents' streaming figure.
Figure 10:PHR-antiCD19CAR-U6-IFN-gama shRNA-T cell-specifics kill the tumour of the CD19 positives
Cell counts figure.
Figure 11:RT-PCR methods detect pHR-antiCD19CAR-U6-IFN-gama shRNA-T cytokine contents.
Figure 12:ELISA detects pHR-antiCD19CAR-U6-IFN-gama shRNA-T cytokine contents.
Specific implementation mode
With reference to embodiment, the present invention is further illustrated.It will be understood to those of skill in the art that following reality
It applies example and is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.Particular technique or condition are not specified in embodiment
Person, according to technology described in document in the art or condition (such as with reference to works such as J. Pehanorm Brookers, what Huang Peitang etc. was translated
《Molecular Cloning:A Laboratory guide》, the third edition, Science Press) or carry out according to product description.
Involved instrument, reagent, material etc., are existing in the prior art unless otherwise noted in following embodiments
Conventional instrument, reagent, material etc., can be obtained by regular commercial sources.Involved experimental method in following embodiments, inspection
Survey method etc. is unless otherwise noted existing routine experiment method in the prior art, detection method etc..
Embodiment 1:The synthesis of the IFN-gama shRNA of carrier can be cloned into
In the sequence of Sigma-Aldrich China official online enquiries IFN-gama shRNA, 4 (gama- therein are chosen
1, gama-2, gama-3, gama-4), nucleotide sequence difference is as follows.
gama-1:CCGGGCAGAGCCAAATTGTCTCCTTCTCGAGAAGGAGACAATTTGGCTCTGCTTTTTG。
gama-2:CCGGTATAAGTGAAGTGATACTATCCTCGAGGATAGTATCACTTCACTTATATTTTTG。
gama-3:CCGGCATTCAGATGTAGCGGATAATCTCGAGATTATCCGCTACATCTGAATGTTTTTG。
gama-4:CCGGGGTTGTCCTGCCTGCAATATTCTCGAGAATATTGCAGGCAGGACAACCTTTTTG。
Wherein, the sequence that underscore marks is the sequence of every middle siRNA.
The present invention uses traditional method for being cloned into carrier, by DNA widow's core of two coding IFN-gamasiRNA sequences
Thuja acid is inserted into carrier.The DNA oligonucleotides contains the just siRNA sequence of 21 nucleotide length, passes through the section of Ambion
The intervening sequence TTCAAGAGA for 9 nucleotide that scholar has successfully used and the antisense siRNA sequence phase of its reverse complemental
Even, 5 T are added as termination signal in 3 ' ends of its oligonucleotides, and is added in design and is cloned into digestion needed for carrier
Site NotI.
The present invention uses 4 primer annealing synthetic methods, 4 primers of respectively every shRNA sequence design, IFN-gama
ShRNA-1 primer sequences such as SEQ ID NO:Shown in 5~8.IFN-gama shRNA-2 primer sequences are as follows.IFN-gama
ShRNA-3 primer sequences such as SEQ ID NO:Shown in 9~12.IFN-gama shRNA-4 primer sequences are as follows.
IFN-gama shRNA-2 primer sequences are as follows:
hIFN-gama-shRNA2-1st:GGCCGCCTATAAGTGAAGTGATACTATCTTCAAGAGA;
hIFN-gama-shRNA2-2nd:GATAGTATCACTTCACTTATATTTTTGC;
hIFN-gama-shRNA2-3rd:GATAGTATCACTTCACTTATAGGC;
hIFN-gama-shRNA2-4th:GGCCGCAAAAATATAAGTGAAGTGATACTATCTCTCTTGAA.
IFN-gama shRNA-4 primer sequences are as follows:
hIFN-gama-shRNA4-1st:GGCCGCCGGTTGTCCTGCCTGCAATATTTTCAAGAGA;
hIFN-gama-shRNA4-2nd:AATATTGCAGGCAGGACAACCTTTTTGC;
hIFN-gama-shRNA4-3rd:AATATTGCAGGCAGGACAACCGGC;
hIFN-gama-shRNA4-4th:GGCCGCAAAAAGGTTGTCCTGCCTGCAATATTTCTCTTGAA.
4 primers of every shRNA are synthesized by the Suzhou bio tech ltd Jin Weizhi, then draw 4 of synthesis
Object dry powder rapid centrifugation, is diluted with water 100uM later, and 1st, 2nd, 3rd, 4th, 2.5ul, four total 10ul, moisturizing is respectively taken to arrive
50ul boils 5~10 minutes, is placed on natural cooling in pot and stays overnight to room temperature, and by the process, four primers complete annealing, shape
At section of DNA double-strand short-movie section.
The DNA double chain short-movie section formed after the process, IFN-gama shRNA-1, sequence such as SEQ ID NO:1
It is shown;IFN-gama shRNA-2, sequence are as follows;IFN-gama shRNA-3, sequence such as SEQ ID NO:2 institutes
Show;IFN-gama shRNA-4, sequence are as follows.
IFN-gama shRNA-2:
GCGGCCGCCTATAAGTGAAGTGATACTATCTTCAAGAGAGATAGTATCACTTCACTTATATTTTT。
IFN-gama shRNA-4:
GCGGCCGCCGGTTGTCCTGCCTGCAATATTTTCAAGAGAAATATTGCAGGCAGGACAACCTTTTT。
Embodiment 2:The structure of IFN-gama shRNA and CD19CAR dual-expression vectors
As shown in Figure 1, CD8 is worn film signal peptide, myc labels, anti-CD19Scfv, CD8 transmembrane region, 4-1BB costimulations
Signaling zone and the active regions CD3ZetaTCR, U6 promoters, IFN-gama shRNA are sequentially cloned into slow virus skeleton plasmid pHR
In, obtaining pHR-antiCD19CAR-U6-IFN-gama shRNA plasmids, (the involved IFN-gama shRNA of experiment have four
Kind, thus obtained plasmid also there are four types of, respectively it is as follows).
The nucleotide of CD8amyc-anti-CD19Scfv-CD8TM-4-1BB-CD3Zeta-U6-IFN-gama shRNA-1
Sequence (such as SEQ ID NO as follows:Shown in 13).
SEQ ID NO:13:
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGCAGAAGCTGAT
CAGCGAGGAGGACCTGACTAGTGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAG
TCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTT
AAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGA
TTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGT
ACACGTTCGGAGGGGGGACCAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGA
TCTGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTC
AGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAA
TATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGC
CAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGG
TGGTAGCTATGCTATGGACTACTGGGGCCAAGGAACCTCAGTCACCGTCTCCTCAGGATCCACCACGACGCCAGCGC
CGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCG
GGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGG
GGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCTCCCTAAAACGGGGCAGAAAGAAACTCCTGTATATATTCA
AACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAA
GGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTA
TAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGG
GAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGT
GAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAA
GGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCGGCTAAAAGGTCGGGCAGGAAGAGGGCCTATTTC
CCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACA
AAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAA
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGGTTTATATATCTTGTGGAAAGGACGGC
GGCCGCCGCAGAGCCAAATTGTCTCCTTTTCAAGAGAAAGGAGACAATTTGGCTCTGCTTTTT。
The nucleotide of CD8amyc-anti-CD19Scfv-CD8TM-4-1BB-CD3Zeta-U6-IFN-gama shRNA-2
Sequence is as follows:
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGCAGAAGCTGAT
CAGCGAGGAGGACCTGACTAGTGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAG
TCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTT
AAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGA
TTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGT
ACACGTTCGGAGGGGGGACCAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGA
TCTGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTC
AGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAA
TATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGC
CAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGG
TGGTAGCTATGCTATGGACTACTGGGGCCAAGGAACCTCAGTCACCGTCTCCTCAGGATCCACCACGACGCCAGCGC
CGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCG
GGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGG
GGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCTCCCTAAAACGGGGCAGAAAGAAACTCCTGTATATATTCA
AACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAA
GGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTA
TAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGG
GAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGT
GAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAA
GGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCGGCTAAAAGGTCGGGCAGGAAGAGGGCCTATTTC
CCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACA
AAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAA
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGGTTTATATATCTTGTGGAAAGGACGGC
GGCCGCCTATAAGTGAAGTGATACTATCTTCAAGAGAGATAGTATCACTTCACTTATATTTTT。
The nucleotide of CD8amyc-anti-CD19Scfv-CD8TM-4-1BB-CD3Zeta-U6-IFN-gama shRNA-3
Sequence (such as SEQ ID NO as follows:Shown in 14).
SEQ ID NO:14:
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGCAGAAGCTGAT
CAGCGAGGAGGACCTGACTAGTGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAG
TCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTT
AAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGA
TTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGT
ACACGTTCGGAGGGGGGACCAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGA
TCTGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTC
AGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAA
TATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGC
CAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGG
TGGTAGCTATGCTATGGACTACTGGGGCCAAGGAACCTCAGTCACCGTCTCCTCAGGATCCACCACGACGCCAGCGC
CGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCG
GGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGG
GGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCTCCCTAAAACGGGGCAGAAAGAAACTCCTGTATATATTCA
AACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAA
GGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTA
TAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGG
GAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGT
GAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAA
GGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCGGCTAAAAGGTCGGGCAGGAAGAGGGCCTATTTC
CCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACA
AAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAA
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGGTTTATATATCTTGTGGAAAGGACGGC
GGCCGCCCATTCAGATGTAGCGGATAATTTCAAGAGAATTATCCGCTACATCTGAATGTTTTT。
The nucleotide of CD8amyc-anti-CD19Scfv-CD8TM-4-1BB-CD3Zeta-U6-IFN-gama shRNA-4
Sequence is as follows:
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGCAGAAGCTGAT
CAGCGAGGAGGACCTGACTAGTGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAG
TCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTT
AAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGA
TTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGT
ACACGTTCGGAGGGGGGACCAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGA
TCTGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTC
AGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAA
TATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGC
CAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGG
TGGTAGCTATGCTATGGACTACTGGGGCCAAGGAACCTCAGTCACCGTCTCCTCAGGATCCACCACGACGCCAGCGC
CGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCG
GGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGG
GGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCTCCCTAAAACGGGGCAGAAAGAAACTCCTGTATATATTCA
AACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAA
GGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTA
TAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGG
GAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGT
GAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAA
GGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCGGCTAAAAGGTCGGGCAGGAAGAGGGCCTATTTC
CCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACA
AAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAA
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGGTTTATATATCTTGTGGAAAGGACGGC
GGCCGCCGGTTGTCCTGCCTGCAATATTTTCAAGAGAAATATTGCAGGCAGGACAACCTTTTT。
Embodiment 3:PHR-IFN-gama-GFP screens the preparation of plasmid
As shown in Fig. 2, IFN-gama, GFP are sequentially cloned into slow virus skeleton plasmid pHR, pHR-IFN- is obtained
Gama-GFP plasmids.GFP is reporter gene in the pHR-IFN-gama-GFP, for detecting the gene silencing of IFN-gama
Efficiency.
The nucleotide sequence of IFN-gama-GFP fusion proteins is as follows:
ATGAAGTACACCAGCTACATCCTGGCCTTTCAGCTGTGCATCGTGCTGGGCAGCCTGGGCTGCTACTGCCAGGACCC
CTACGTGAAGGAGGCCGAGAACCTGAAGAAGTACTTCAACGCCGGCCACAGCGACGTGGCCGACAACGGCACCCTGT
TCCTCGGCATCCTGAAGAACTGGAAGGAGGAGAGCGACAGGAAGATCATGCAGTCCCAGATCGTGAGCTTCTACTTC
AAGCTGTTCAAGAATTTCAAGGACGACCAGAGCATCCAGAAGAGCGTGGAGACCATCAAGGAGGACATGAACGTGAA
GTTTTTCAATAGCAACAAGAAGAAGAGGGACGACTTCGAGAAGCTGACCAACTACAGCGTGACCGACCTGAATGTGC
AGAGGAAGGCCATCCACGAACTGATCCAGGTGATGGCCGAGCTGAGCCCTGCCGCCAAGACCGGCAAGAGGAAGAGG
AGCCAGATGCTGTTCAGGGGCAGGAGGGCCAGCCAGGGATCCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT
GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATG
CCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACC
ACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCAT
GCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGT
TCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC
AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTT
CAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACG
GCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGAT
CACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA。
Embodiment 4:The pHR-antiCD19CAR-U6-IFN-gama shRNA slow virus of effective reticence IFN-gama expression
The screening of carrier
(1) pHR-IFN-gama-GFP screens the transfection of plasmid
Using calcium phosphate transfection method, by CaCl2, plasmid and water mix according to a certain percentage, be slowly dropped to 293FT cells
Culture supernatant in, for 24 hours after flow cytometer detection 293FT, detect the luciferase expression of IFN-gama-GFP fusion proteins.As shown in Figure 3
The transfection efficiency of pHR-IFN-gama-GFP is 48.3%, being capable of Successful transfection.
(2) transfection of pHR-antiCD19CAR-U6-IFN-gamashRNA plasmids
Using calcium phosphate transfection method, by CaCl2, plasmid and water mix according to a certain percentage, be slowly dropped to 293FT cells
Culture supernatant in, take 293FT cells, the cell proportion (Fluorescein of the flow cytomery CAR positives afterwards for 24 hours
(FITC) AffiniPure Goat Anti-Mouse IgG, F (ab') 2fragment specific, jackson
Immunoresearch, cat:115-095-006).As shown in figure 4, being compared with negative control group, 4 kinds of pHR-
The transfection efficiency of antiCD19CAR-U6-IFN-gama shRNA plasmids is respectively 19.8%, 25%, 20.6%, 15.7%.All
It being capable of Successful transfection.
(3) RT-PCR methods screening IFN-gama shRNA
Using the side of pHR-IFN-gama-GFP and pHR-antiCD19CAR-U6-IFN-gama shRNA plasmid co-transfections
Formula, by calcium phosphate transfection method, by CaCl2, 2 kinds of plasmids and water mix according to a certain percentage, be slowly dropped to 293FT cells
In culture supernatant, 293FT cells, extraction total serum IgE (MiniBEST Universal RNA, TAKARA, cat are harvested afterwards for 24 hours:
9767), reverse transcription is at cDNA (FastKing RT Kit, Tiangeng, cat:KR11601), using the primer of IFN-gama (as before
It is shown), the expression of IFN-gama in mRNA level in-site is measured by the method for quantitative fluorescent PCR (need to use reference gene β-actin
Primer, as previously shown).
As shown in figure 5, being compared with the 293FT that pHR-IFN-gama-GFP is individually transfected, pHR-antiCD19CAR-U6-
IFN-gama shRNA-1 plasmids, pHR-antiCD19CAR-U6-IFN-gama shRNA-3 plasmids and pHR-IFN-gama-
The level of IFN-gama is substantially reduced in 293FT after GFP cotransfections.Statistical analysis shows that the level of IFN-gama has significantly
Difference.Show that this 2 kinds of pHR-antiCD19CAR-U6-IFN-gamashRNA can effectively reduce pHR-IFN- in mRNA level in-site
The expression of IFN-gama in gama-GFP, plays the effect of gene silencing.
(4) screening of streaming method IFN-gama shRNA
Using the side of pHR-IFN-gama-GFP and pHR-antiCD19CAR-U6-IFN-gama shRNA plasmid co-transfections
Formula, by calcium phosphate transfection method, by CaCl2, 2 kinds of plasmids and water mix according to a certain percentage, be slowly dropped to 293FT cells
In culture supernatant, rear flow cytometer detection 293FT, detects the luciferase expression of IFN-gama-GFP fusion proteins for 24 hours.As shown in fig. 6, and
The transfection efficiency that pHR-IFN-gama-GFP individually transfects 17% is compared, pHR-antiCD19CAR-U6-IFN-gama shRNA-
GFP after 1 plasmid, pHR-antiCD19CAR-U6-IFN-gama shRNA-3 plasmids and pHR-IFN-gama-GFP cotransfections
It is 7.55%, 4.16% that transfection efficiency, which is remarkably decreased,.Show this 2 kinds of pHR-antiCD19CAR-U6-IFN-gama shRNA energy
The protein expression for effectively reducing IFN-gama in pHR-IFN-gama-GFP, plays the effect of gene silencing.
Embodiment 5:The packaging of slow virus and concentration
By the Lentiviral (pHR-antiCD19CAR-U6-IFN-gama for carrying target gene
ShRNA-1 plasmids and pHR-antiCD19CAR-U6-IFN-gama shRNA-3 plasmids), pCMV carriers and pMD.2G carriers it is mixed
It is transfected into after conjunction in 293FT cells, 6~8h is changed to complete medium culture after transfection, culture solution is collected after 48h, after centrifugation
Retain supernatant and filtered with 0.45 μm of filter, retains filtrate, the filtrate is the solution of recombinant slow virus.
Slow virus concentrates according to Lenti-XTMConcentrator (takara, cat:631231) specification carries out.
Embodiment 6:The preparation of the T cell of IFN-gama shRNA and CD19CAR dual-expression vectors
50mL new bloods are taken, it is single to detach to carry out density gradient centrifugation by lymphocyte separation medium (oceans Tianjin Hao)
Nucleus.Mononuclearcell is resuspended into X-VIVO15 culture mediums (Lonza), while adding CD3 monoclonal antibodies and CD28 monoclonal antibodies
Activated T lymphocytes, 37 DEG C of 5%CO2Culture 48 hours.
Take 2 × 106Cell, 2 kinds of slow virus concentrating in embodiment 5 are added according to MOI=5, at the same be added IL-2 and
Polybrene, mixing, 37 DEG C of 5%CO2Culture 6-8 hours, it is that fresh X-VIVO15 culture mediums (contain that liquid is changed in 300g5min centrifugations
IL-2)。
Fresh X-VIVO15 culture mediums (containing IL-2) were added per 2-3 days, maintain cell density 1 × 106/ mL or so expands
Increase 10-12 days.
The T cell each 5 × 10 of the T cell and uninfecting virus of culture 48h after taking virus to infect5, each sample adds
FluoresceinAffiniPure Goat Anti-Mouse IgG, F (ab') 2fragmentspecific1ul, room temperature are protected from light
It is incubated 15min, centrifugation, precipitation upper machine testing (Millipore guava easyCyteHT) after being resuspended with 200 μ LPBS.As a result
As shown in fig. 7,2 kinds of pHR-antiCD19CAR-U6-IFN-gama shRNA-T are thin in the T cell of culture 48h after virus infection
The ratio of born of the same parents is 84.9%, 86.6%, and efficiency of infection is very high.Prepared in the embodiment 2 kinds of T cells are named as pHR-
AntiCD19CAR-U6-IFN-gama shRNA-1-T and pHR-antiCD19CAR-U6-IFN-gama shRNA-3-T, as
Used cell in later embodiment.
Embodiment 7:The Cytotoxicity in vitro of pHR-antiCD19CAR-U6-IFN-gama shRNA-T cells against tumor cells strains
Experiment
1. stablizing the structure of the K562 cells (target cell) of expression CD19 genes
(1) the DNA encoding sequence for synthesizing CD19 extracellular regions and transmembrane region, is inserted into pHR carriers, builds the carrier name of acquisition
For pHR-CD19.
CD19 extracellular regions and the nucleotide coding sequence of transmembrane region are as follows:
ATGCCACCTCCTCGCCTCCTCTTCTTCCTCCTCTTCCTCACCCCCATGGAAGTCAGGCCCGAGGAACCTCTAGTGGT
GAAGGTGGAAGAGGGAGATAACGCTGTGCTGCAGTGCCTCAAGGGGACCTCAGATGGCCCCACTCAGCAGCTGACCT
GGTCTCGGGAGTCCCCGCTTAAACCCTTCTTAAAACTCAGCCTGGGGCTGCCAGGCCTGGGAATCCACATGAGGCCC
CTGGCCATCTGGCTTTTCATCTTCAACGTCTCTCAACAGATGGGGGGCTTCTACCTGTGCCAGCCGGGGCCCCCCTC
TGAGAAGGCCTGGCAGCCTGGCTGGACAGTCAATGTGGAGGGCAGCGGGGAGCTGTTCCGGTGGAATGTTTCGGACC
TAGGTGGCCTGGGCTGTGGCCTGAAGAACAGGTCCTCAGAGGGCCCCAGCTCCCCTTCCGGGAAGCTCATGAGCCCC
AAGCTGTATGTGTGGGCCAAAGACCGCCCTGAGATCTGGGAGGGAGAGCCTCCGTGTCTCCCACCGAGGGACAGCCT
GAACCAGAGCCTCAGCCAGGACCTCACCATGGCCCCTGGCTCCACACTCTGGCTGTCCTGTGGGGTACCCCCTGACT
CTGTGTCCAGGGGCCCCCTCTCCTGGACCCATGTGCACCCCAAGGGGCCTAAGTCATTGCTGAGCCTAGAGCTGAAG
GACGATCGCCCGGCCAGAGATATGTGGGTAATGGAGACGGGTCTGTTGTTGCCCCGGGCCACAGCTCAAGACGCTGG
AAAGTATTATTGTCACCGTGGCAACCTGACCATGTCATTCCACCTGGAGATCACTGCTCGGCCAGTACTATGGCACT
GGCTGCTGAGGACTGGTGGCTGGAAGGTCTCAGCTGTGACTTTGGCTTATCTGATCTTCTGCCTGTGTTCCCTTGTG
GGCATTCTTCATCTTCAAAGAGCCCTGGTCCTGAGG。
(2) slow virus packaging and concentration
It is transfected into 293FT cells after the pHR-CD19 carriers, pCMV carriers and pMD.2G carriers are mixed, after transfection
6~8h is changed to complete medium culture, and culture solution is collected after 48h, and supernatant is retained after centrifugation and is filtered with 0.45 μm of filter, is protected
Reserved filtrate, the filtrate are the solution of recombinant slow virus.
Slow virus concentrates according to Lenti-XTMConcentrator (takara, cat:631231) specification carries out.
(3) preparation of the K562 cells of expression CD19
K562 cells are resuspended to 1x10 in 1640 (Gibco) culture mediums6/ mL, is added slow virus (MOI5-10), 37 DEG C, 5%
CO2Incubator culture 6-8h, it is fresh K562 cell Proliferations culture solution that liquid is changed in centrifugation.Fresh K562 cells were added per 2-3 days to increase
Culture solution is grown, maintains cell density in 0.5x106/ mL or so.After 5 generations, monoclonal screening is carried out using limiting dilution assay.Wait for list
Clone cell is grown to certain amount, and (anti-CD19PE, biolegend cat is screened by flow cytometer:
302254) cell clone that, expression quantity is high and purity is high, as stablizes the K562 cells of expression CD19, is named as K562-CD19
(as shown in Figure 8), as the target cell in the present embodiment.
The killing ability Validation in vitro of 2.pHR-antiCD19CAR-U6-IFN-gama shRNA-T
The K562-CD19 cells of K562 cells and structure are pressed 1:1 is inoculated in 96 orifice plates, by E:T=1:1,3:1 difference
9 days pHR-antiCD19CAR-U6-IFN-gama shRNA-1-T of inoculated and cultured, pHR-antiCD19CAR-U6-IFN-
Gama shRNA-3-T, antiCD19CAR-T cells and T cell.37 DEG C of 5%CO2Culture 24 hours is drawn per hole on 100 μ L
- 80 DEG C of clear liquid saves backup.PE anti-humanCD19 (Biolegend) and FITCanti- are added per hole for remaining cell
Human CD3 (Biolegend), room temperature, which is protected from light, is incubated 15min, centrifugation, precipitation upper machine testing after being resuspended with 200 μ L PBS
(Millipore guava easyCyteHT).As a result as shown in FIG. 9 and 10,2 groups of pHR-antiCD19CAR-U6-IFN-
It is 1 that gama shRNA-T cells have specific killing, effect target ratio to K562-CD19 cells:1,3:Specific killing efficiency is equal when 1
Value be respectively 56.7%, 100% and 63.3%, 100%, killing rate with effect target than increase and increase.Statistical analysis shows,
Specific killing efficiency between 2 groups of pHR-antiCD19CAR-U6-IFN-gama shRNA-T cells and T cell group has significantly
Difference, and the specificity between pHR-antiCD19CAR-U6-IFN-gama shRNA-T and antiCD19CAR-T groups of cells is killed
Hinder efficiency without significant difference.
Embodiment 8:PHR-antiCD19CAR-U6-IFN-gamashRNA-T cell cytokine content detections
1) RT-PCR methods detect pHR-antiCD19CAR-U6-IFN-gama shRNA-T cytokine releases
Take pHR-antiCD19CAR-U6-IFN-gamashRNA-1-T, pHR-antiCD19CAR-U6- of culture 9 days
IFN-gama shRNA-3-T and antiCD19CAR-T cells, extraction total serum IgE (MiniBEST Universal RNA,
TAKARA,cat:9767), reverse transcription is at cDNA (FastKing RTKit, Tiangeng, cat:KR11601), the primer of IL-6 is utilized
The primer (as previously shown) of (as follows), IFN-gama, the primer (as follows) of IL-2, house-keeping gene β-action draw
Object (as previously shown) measures the expression of IL-6, IFN-gama, IL-2 in mRNA level in-site by the method for quantitative fluorescent PCR.
The primer sequence of IL-6 is as follows in RT-PCR:IL-6-F:AGACAGCCACTCACCTCTTCAG;IL-6-R:
TTCTGCCAGTGCCTCTTTGCTG。
The primer sequence of IL-2 is as follows in RT-PCR:IL-2-F:AACTCACCAGGATGCTCACATTTA;IL-2-
R:TCCCTGGGTCTTAAGTGAAAGTTT。
It is compared as shown in figure 11 with CD19CAR-T cells, pHR-antiCD19CAR-U6-IFN-gama shRNA-T are thin
Born of the same parents can significantly reduce the release of IFN-gama, IL-6 and IL-2 in mRNA level in-site, play the effect of gene silencing IL-6.
2) secreted in ELISA method detection pHR-antiCD19CAR-U6-IFN-gama shRNA-T cells and supernatants because
Sub- content
E in Example 7:T=3:The stayed supernatant of 1 killing experiment in vitro, respectively T cell group, antiCD19CAR-T
Groups of cells, pHR-antiCD19CAR-U6-IFN-gama shRNA-1-T groups of cells, pHR-antiCD19CAR-U6-IFN-
The supernatant of gama shRNA-3-T groups of cells and the negative control group of tumour cell, by HumanI L-
2ELISAMAXTMDeluxe (Biolegend, 431804), Human IFN-gama ELISAMAXTMDeluxe (Biolegend,
430104)、HumanIL-6ELISAMAXTMDeluxe (Biolegend, 430504) kit specification operates, and detects IFN-
The release of gama, IL-6 and IL-2.
As a result as shown in figure 12, pHR-antiCD19CAR-U6-IFN-gama shRNA-T cells and CD19CAR-T cells
Compared to the release that can significantly reduce IFN-gama.Reduce the release of IL-6.And the release of IL-2 is had not significant impact.
Above-described embodiment is provided to those skilled in the art, how to implement and use to be advocated with full disclosure and description
Embodiment, rather than for limiting range disclosed herein.Obvious modification will to those skilled in the art
Within the scope of the appended claims.The all publications, patents and patent applications of this specification citation are incorporated by reference into this
Text, as these publications, patents and patent applications respectively particularly and individually show to be incorporated herein by reference.
Sequence table
<110>Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
<120>Interfere CD19-CAR-T cells and its application of IFN-gama expression
<141> 2018-04-27
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 65
<212> DNA
<213> Artificial Sequence
<400> 1
gcggccgccg cagagccaaa ttgtctcctt ttcaagagaa aggagacaat ttggctctgc 60
ttttt 65
<210> 2
<211> 65
<212> DNA
<213> Artificial Sequence
<400> 2
gcggccgccc attcagatgt agcggataat ttcaagagaa ttatccgcta catctgaatg 60
ttttt 65
<210> 3
<211> 499
<212> PRT
<213> Artificial Sequence
<400> 3
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15
His Ala Ala Arg Pro Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asp
20 25 30
Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp
35 40 45
Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr Leu
50 55 60
Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr
65 70 75 80
His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
85 90 95
Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu
100 105 110
Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr
115 120 125
Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Gly Gly Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Glu Ser
145 150 155 160
Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr
165 170 175
Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln
180 185 190
Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu
195 200 205
Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys
210 215 220
Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr
225 230 235 240
Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly
245 250 255
Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser
260 265 270
Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
275 280 285
Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
290 295 300
Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
305 310 315 320
Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
325 330 335
Val Ile Thr Leu Tyr Cys Ser Leu Lys Arg Gly Arg Lys Lys Leu Leu
340 345 350
Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu
355 360 365
Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys
370 375 380
Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys
385 390 395 400
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
405 410 415
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
420 425 430
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
435 440 445
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
450 455 460
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
465 470 475 480
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
485 490 495
Pro Arg Gly
<210> 4
<211> 1512
<212> DNA
<213> Artificial Sequence
<400> 4
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
ccggagcaga agctgatcag cgaggaggac ctgactagtg acatccagat gacacagact 120
acatcctccc tgtctgcctc tctgggagac agagtcacca tcagttgcag ggcaagtcag 180
gacattagta aatatttaaa ttggtatcag cagaaaccag atggaactgt taaactcctg 240
atctaccata catcaagatt acactcagga gtcccatcaa ggttcagtgg cagtgggtct 300
ggaacagatt attctctcac cattagcaac ctggagcaag aagatattgc cacttacttt 360
tgccaacagg gtaatacgct tccgtacacg ttcggagggg ggaccaagct ggagatcaca 420
ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatctgaggt gaaactgcag 480
gagtcaggac ctggcctggt ggcgccctca cagagcctgt ccgtcacatg cactgtctca 540
ggggtctcat tacccgacta tggtgtaagc tggattcgcc agcctccacg aaagggtctg 600
gagtggctgg gagtaatatg gggtagtgaa accacatact ataattcagc tctcaaatcc 660
agactgacca tcatcaagga caactccaag agccaagttt tcttaaaaat gaacagtctg 720
caaactgatg acacagccat ttactactgt gccaaacatt attactacgg tggtagctat 780
gctatggact actggggcca aggaacctca gtcaccgtct cctcaggatc caccacgacg 840
ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc 900
ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc 960
tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg 1020
gttatcaccc tttactgctc cctaaaacgg ggcagaaaga aactcctgta tatattcaaa 1080
caaccattta tgagaccagt acaaactact caagaggaag atggctgtag ctgccgattt 1140
ccagaagaag aagaaggagg atgtgaactg agagtgaagt tcagcaggag cgcagacgcc 1200
cccgcgtaca agcagggcca gaaccagctc tataacgagc tcaatctagg acgaagagag 1260
gagtacgatg ttttggacaa gagacgtggc cgggaccctg agatgggggg aaagccgaga 1320
aggaagaacc ctcaggaagg cctgtacaat gaactgcaga aagataagat ggcggaggcc 1380
tacagtgaga ttgggatgaa aggcgagcgc cggaggggca aggggcacga tggcctttac 1440
cagggtctca gtacagccac caaggacacc tacgacgccc ttcacatgca ggccctgccc 1500
cctcgcggct aa 1512
<210> 5
<211> 37
<212> DNA
<213> Artificial Sequence
<400> 5
ggccgccgca gagccaaatt gtctcctttt caagaga 37
<210> 6
<211> 28
<212> DNA
<213> Artificial Sequence
<400> 6
aaggagacaa tttggctctg ctttttgc 28
<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 7
aaggagacaa tttggctctg cggc 24
<210> 8
<211> 41
<212> DNA
<213> Artificial Sequence
<400> 8
ggccgcaaaa agcagagcca aattgtctcc tttctcttga a 41
<210> 9
<211> 37
<212> DNA
<213> Artificial Sequence
<400> 9
ggccgcccat tcagatgtag cggataattt caagaga 37
<210> 10
<211> 28
<212> DNA
<213> Artificial Sequence
<400> 10
attatccgct acatctgaat gtttttgc 28
<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 11
attatccgct acatctgaat gggc 24
<210> 12
<211> 41
<212> DNA
<213> Artificial Sequence
<400> 12
ggccgcaaaa acattcagat gtagcggata attctcttga a 41
<210> 13
<211> 1834
<212> DNA
<213> Artificial Sequence
<400> 13
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
ccggagcaga agctgatcag cgaggaggac ctgactagtg acatccagat gacacagact 120
acatcctccc tgtctgcctc tctgggagac agagtcacca tcagttgcag ggcaagtcag 180
gacattagta aatatttaaa ttggtatcag cagaaaccag atggaactgt taaactcctg 240
atctaccata catcaagatt acactcagga gtcccatcaa ggttcagtgg cagtgggtct 300
ggaacagatt attctctcac cattagcaac ctggagcaag aagatattgc cacttacttt 360
tgccaacagg gtaatacgct tccgtacacg ttcggagggg ggaccaagct ggagatcaca 420
ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatctgaggt gaaactgcag 480
gagtcaggac ctggcctggt ggcgccctca cagagcctgt ccgtcacatg cactgtctca 540
ggggtctcat tacccgacta tggtgtaagc tggattcgcc agcctccacg aaagggtctg 600
gagtggctgg gagtaatatg gggtagtgaa accacatact ataattcagc tctcaaatcc 660
agactgacca tcatcaagga caactccaag agccaagttt tcttaaaaat gaacagtctg 720
caaactgatg acacagccat ttactactgt gccaaacatt attactacgg tggtagctat 780
gctatggact actggggcca aggaacctca gtcaccgtct cctcaggatc caccacgacg 840
ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc 900
ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc 960
tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg 1020
gttatcaccc tttactgctc cctaaaacgg ggcagaaaga aactcctgta tatattcaaa 1080
caaccattta tgagaccagt acaaactact caagaggaag atggctgtag ctgccgattt 1140
ccagaagaag aagaaggagg atgtgaactg agagtgaagt tcagcaggag cgcagacgcc 1200
cccgcgtaca agcagggcca gaaccagctc tataacgagc tcaatctagg acgaagagag 1260
gagtacgatg ttttggacaa gagacgtggc cgggaccctg agatgggggg aaagccgaga 1320
aggaagaacc ctcaggaagg cctgtacaat gaactgcaga aagataagat ggcggaggcc 1380
tacagtgaga ttgggatgaa aggcgagcgc cggaggggca aggggcacga tggcctttac 1440
cagggtctca gtacagccac caaggacacc tacgacgccc ttcacatgca ggccctgccc 1500
cctcgcggct aaaaggtcgg gcaggaagag ggcctatttc ccatgattcc ttcatatttg 1560
catatacgat acaaggctgt tagagagata attagaatta atttgactgt aaacacaaag 1620
atattagtac aaaatacgtg acgtagaaag taataatttc ttgggtagtt tgcagtttta 1680
aaattatgtt ttaaaatgga ctatcatatg cttaccgtaa cttgaaagta tttcgatttc 1740
ttgggtttat atatcttgtg gaaaggacgg cggccgccgc agagccaaat tgtctccttt 1800
tcaagagaaa ggagacaatt tggctctgct tttt 1834
<210> 14
<211> 1834
<212> DNA
<213> Artificial Sequence
<400> 14
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
ccggagcaga agctgatcag cgaggaggac ctgactagtg acatccagat gacacagact 120
acatcctccc tgtctgcctc tctgggagac agagtcacca tcagttgcag ggcaagtcag 180
gacattagta aatatttaaa ttggtatcag cagaaaccag atggaactgt taaactcctg 240
atctaccata catcaagatt acactcagga gtcccatcaa ggttcagtgg cagtgggtct 300
ggaacagatt attctctcac cattagcaac ctggagcaag aagatattgc cacttacttt 360
tgccaacagg gtaatacgct tccgtacacg ttcggagggg ggaccaagct ggagatcaca 420
ggtggcggtg gctcgggcgg tggtgggtcg ggtggcggcg gatctgaggt gaaactgcag 480
gagtcaggac ctggcctggt ggcgccctca cagagcctgt ccgtcacatg cactgtctca 540
ggggtctcat tacccgacta tggtgtaagc tggattcgcc agcctccacg aaagggtctg 600
gagtggctgg gagtaatatg gggtagtgaa accacatact ataattcagc tctcaaatcc 660
agactgacca tcatcaagga caactccaag agccaagttt tcttaaaaat gaacagtctg 720
caaactgatg acacagccat ttactactgt gccaaacatt attactacgg tggtagctat 780
gctatggact actggggcca aggaacctca gtcaccgtct cctcaggatc caccacgacg 840
ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc 900
ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc 960
tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg 1020
gttatcaccc tttactgctc cctaaaacgg ggcagaaaga aactcctgta tatattcaaa 1080
caaccattta tgagaccagt acaaactact caagaggaag atggctgtag ctgccgattt 1140
ccagaagaag aagaaggagg atgtgaactg agagtgaagt tcagcaggag cgcagacgcc 1200
cccgcgtaca agcagggcca gaaccagctc tataacgagc tcaatctagg acgaagagag 1260
gagtacgatg ttttggacaa gagacgtggc cgggaccctg agatgggggg aaagccgaga 1320
aggaagaacc ctcaggaagg cctgtacaat gaactgcaga aagataagat ggcggaggcc 1380
tacagtgaga ttgggatgaa aggcgagcgc cggaggggca aggggcacga tggcctttac 1440
cagggtctca gtacagccac caaggacacc tacgacgccc ttcacatgca ggccctgccc 1500
cctcgcggct aaaaggtcgg gcaggaagag ggcctatttc ccatgattcc ttcatatttg 1560
catatacgat acaaggctgt tagagagata attagaatta atttgactgt aaacacaaag 1620
atattagtac aaaatacgtg acgtagaaag taataatttc ttgggtagtt tgcagtttta 1680
aaattatgtt ttaaaatgga ctatcatatg cttaccgtaa cttgaaagta tttcgatttc 1740
ttgggtttat atatcttgtg gaaaggacgg cggccgccca ttcagatgta gcggataatt 1800
tcaagagaat tatccgctac atctgaatgt tttt 1834
Claims (10)
1. interfering the shRNA of people's IFN-gama gene expressions, it is characterised in that:For IFN-gama shRNA-1 or IFN-gama
The nucleotide sequence of shRNA-3, IFN-gama shRNA-1 are as follows, and the nucleotide sequence of IFN-gama shRNA-3 is as follows
It is shown:
IFN-gama shRNA-1, such as SEQ ID NO:Shown in 1:
GCGGCCGCCGCAGAGCCAAATTGTCTCCTTTTCAAGAGAAAGGAGACAATTTGGCTCTGCTTTTT。
IFN-gama shRNA-3, such as SEQ ID NO:Shown in 2:
GCGGCCGCCCATTCAGATGTAGCGGATAATTTCAAGAGAATTATCCGCTACATCTGAATGTTTTT。
2. being used to prepare the primer of the shRNA of interference people's IFN-gama gene expressions described in claim 1, it is characterised in that:
It is used to prepare the primer of IFN-gama shRNA-1, nucleotide sequence is as follows:
hIFN-gama-shRNA1-1st:GGCCGCCGCAGAGCCAAATTGTCTCCTTTTCAAGAGA;
hIFN-gama-shRNA1-2nd:AAGGAGACAATTTGGCTCTGCTTTTTGC;
hIFN-gama-shRNA1-3rd:AAGGAGACAATTTGGCTCTGCGGC;
hIFN-gama-shRNA1-4th:GGCCGCAAAAAGCAGAGCCAAATTGTCTCCTTTCTCTTGAA.
It is used to prepare the primer of IFN-gama shRNA-3, nucleotide sequence is as follows:
hIFN-gama-shRNA3-1st:GGCCGCCCATTCAGATGTAGCGGATAATTTCAAGAGA;
hIFN-gama-shRNA3-2nd:ATTATCCGCTACATCTGAATGTTTTTGC;
hIFN-gama-shRNA3-3rd:ATTATCCGCTACATCTGAATGGGC;
hIFN-gama-shRNA3-4th:GGCCGCAAAAACATTCAGATGTAGCGGATAATTCTCTTGAA.
3. a kind of Lentiviral, it is characterised in that:It includes the interference people's IFN-gama genes having the right described in requirement 1
The shRNA of expression and the nucleotide fragments of encoding chimeric antigen receptor;The nucleotide piece of the encoding chimeric antigen receptor
Section, nucleotide sequence such as SEQ ID NO:Shown in 4.
4. Lentiviral according to claim 3, it is characterised in that:The structure of the Lentiviral is
PHR-antiCD19CAR-U6-IFN-gama shRNA-1, the nucleotide sequence such as SEQ ID NO of expressing gene:Shown in 13;
Or:PHR-antiCD19CAR-U6-IFN-gama shRNA-3, the nucleotide sequence such as SEQ ID NO of expressing gene:14 institutes
Show.
5. a kind of slow virus expresses kit, include the Lentiviral of claim 3 or 4.
6. a kind of recombinant slow virus, which is characterized in that be prepared by the following method to obtain:By the slow virus table of claim 3 or 4
It is transfected into 293FT cells after being mixed up to carrier, pCMV carriers and pMD.2G carriers, 6~8h is changed to complete culture after transfection
Base culture collects culture solution after 48h, and supernatant is retained after centrifugation and is filtered with 0.45 μm of filtering head, reservation filtrate, as recombinant lentiviral
The solution of virus.
7. a kind of CD19-CAR-T cells of interference people's IFN-gama gene expressions, it is characterised in that:To include claim 3
Or 4 Lentiviral T lymphocytes or chromosome in be integrated with interference people IFN-gama described in claim 1
The T lymphocytes of the shRNA of gene expression and the nucleotide fragments of encoding chimeric antigen receptor;The encoding chimeric antigen
The nucleotide fragments of receptor, nucleotide sequence such as SEQ ID NO:Shown in 4.
8. the Lentiviral described in claim 3 or 4 is pernicious swollen in preparation prevention and/or treatment and/or auxiliary treatment
Application in the drug of tumor.
9. the CD19-CAR-T cells of interference people's IFN-gama gene expressions described in claim 7 prevent and/or control preparing
Application in the drug for the treatment of and/or adjuvant therapy of malignant tumor.
10. application according to claim 8 or claim 9, it is characterised in that:The malignant tumour is selected from the white blood of acute lymphoblastic
Disease and/or chronic lymphocytic leukemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810412693.3A CN108753773B (en) | 2018-05-03 | 2018-05-03 | CD19-CAR-T cell capable of interfering IFN-gama expression and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810412693.3A CN108753773B (en) | 2018-05-03 | 2018-05-03 | CD19-CAR-T cell capable of interfering IFN-gama expression and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108753773A true CN108753773A (en) | 2018-11-06 |
CN108753773B CN108753773B (en) | 2021-03-30 |
Family
ID=64009265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810412693.3A Active CN108753773B (en) | 2018-05-03 | 2018-05-03 | CD19-CAR-T cell capable of interfering IFN-gama expression and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108753773B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112481284A (en) * | 2020-12-07 | 2021-03-12 | 深圳市瑞吉生物科技有限公司 | mRNA (messenger ribonucleic acid) for coding CAR (cancer cell receptor) gene, combined mRNA, construction method, CAR-T cell and application |
CN113088540A (en) * | 2020-01-08 | 2021-07-09 | 上海交通大学医学院附属瑞金医院 | GM-CSF-knocked-down T cell and application thereof |
WO2021179967A1 (en) * | 2020-03-09 | 2021-09-16 | 四川大学华西医院 | APPLICATION OF IFN-γ IN PREPARING ANTI-TUMOR ADJUVANT DRUG |
CN114350665A (en) * | 2022-01-19 | 2022-04-15 | 上海优替济生生物医药有限公司 | IFN-gamma inhibitors and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060178334A1 (en) * | 2005-02-04 | 2006-08-10 | City Of Hope | Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon |
WO2011079070A1 (en) * | 2009-12-23 | 2011-06-30 | Gradalis, Inc. | Furin-knockdown bi-functional rna |
WO2017114497A1 (en) * | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
CN107226867A (en) * | 2017-07-25 | 2017-10-03 | 重庆精准生物技术有限公司 | The Chimeric antigen receptor of anti human CD 19 antigen and its application |
CN107365798A (en) * | 2017-07-13 | 2017-11-21 | 山东省齐鲁细胞治疗工程技术有限公司 | A kind of CD19 CAR T cells of carrying iCasp9 suicide genes and its application |
-
2018
- 2018-05-03 CN CN201810412693.3A patent/CN108753773B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060178334A1 (en) * | 2005-02-04 | 2006-08-10 | City Of Hope | Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon |
WO2011079070A1 (en) * | 2009-12-23 | 2011-06-30 | Gradalis, Inc. | Furin-knockdown bi-functional rna |
WO2017114497A1 (en) * | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
CN107365798A (en) * | 2017-07-13 | 2017-11-21 | 山东省齐鲁细胞治疗工程技术有限公司 | A kind of CD19 CAR T cells of carrying iCasp9 suicide genes and its application |
CN107226867A (en) * | 2017-07-25 | 2017-10-03 | 重庆精准生物技术有限公司 | The Chimeric antigen receptor of anti human CD 19 antigen and its application |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113088540A (en) * | 2020-01-08 | 2021-07-09 | 上海交通大学医学院附属瑞金医院 | GM-CSF-knocked-down T cell and application thereof |
WO2021179967A1 (en) * | 2020-03-09 | 2021-09-16 | 四川大学华西医院 | APPLICATION OF IFN-γ IN PREPARING ANTI-TUMOR ADJUVANT DRUG |
CN115427055A (en) * | 2020-03-09 | 2022-12-02 | 四川大学华西医院 | Application of IFN-gamma in preparation of anti-tumor auxiliary medicine |
CN112481284A (en) * | 2020-12-07 | 2021-03-12 | 深圳市瑞吉生物科技有限公司 | mRNA (messenger ribonucleic acid) for coding CAR (cancer cell receptor) gene, combined mRNA, construction method, CAR-T cell and application |
CN114350665A (en) * | 2022-01-19 | 2022-04-15 | 上海优替济生生物医药有限公司 | IFN-gamma inhibitors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108753773B (en) | 2021-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108753774A (en) | Interfere CD19-CAR-T cells and its application of IL-6 expression | |
US20180369285A1 (en) | Specific Chimeric Antigen Receptor T Cells Targeting To NKG2DL, Its Preparation Method and Application Thereof | |
WO2020108645A1 (en) | Cd19-and bcma-based combined car-t immunotherapy | |
CN108373504A (en) | CD24 specific antibodies and anti-CD24-CAR-T cells | |
CN108753773A (en) | Interfere CD19-CAR-T cells and its application of IFN-gama expression | |
CN106574272A (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
CN109111525B (en) | HLA-G chimeric antigen receptor, coding sequence, expression vector and application | |
CN107033248A (en) | Recognize Chimeric antigen receptor and its application of carcinomebryonic antigen | |
CN107365798A (en) | A kind of CD19 CAR T cells of carrying iCasp9 suicide genes and its application | |
CN111675765A (en) | Armed chimeric antigen receptor cell of targeted coronavirus SPIKE, preparation method and application | |
CN113416260B (en) | Claudin18.2-targeted specific chimeric antigen receptor cell and preparation method and application thereof | |
CN110606893A (en) | Method for treating tumor by chimeric antigen receptor T cell targeting CD19 and CD20 double antigens | |
CN106467906A (en) | Construct, transgenic lymphocyte and its production and use | |
CN111925451A (en) | BCMA (brain cell activating antigen) -targeted Chimeric Antigen Receptor (CAR) and application thereof | |
CN114517185B (en) | Chimeric antigen receptor NK cell, preparation method and application thereof | |
CN111205361B (en) | Interleukin 21 protein (IL21) mutant and application thereof | |
CN110257429A (en) | The T cell and their application of recombinant expression carrier, targeting | |
WO2020248486A1 (en) | Method for preparing car-t that uses tcm as main effective ingredient and use thereof | |
WO2020019983A1 (en) | Genetically engineered cell used for treating tumour | |
CN110204619B (en) | Chimeric antigen receptor comprising Fc gamma RI and uses thereof | |
JP2021536256A (en) | Conditional active chimeric antigen receptor for modified T cells | |
CN116239692B (en) | Isolated antibodies, CARs comprising the antibodies, and uses thereof | |
CN112048021A (en) | ROR 2-targeted chimeric antigen receptor, expression gene, expression vector, T cell and application thereof | |
CN116143943B (en) | Targeting BAFFR chimeric antigen receptor, CAR-T cell and application | |
CN116589584A (en) | Antibodies or fragments thereof targeting human Nectin4 protein and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 250101 office area 117-b3 of customs supervision warehouse in Jinan comprehensive free trade zone, No. 5999, Hangtian Avenue, high tech Zone, Jinan, Shandong (business place: Room 201, second floor, phase I, Yinfeng Biotechnology Park, Gangyuan Sixth Road) Patentee after: QILU CELL THERAPY TECHNOLOGY CO.,LTD. Address before: 250101 Export Processing Zone, Jinan High-tech Zone, Shandong Province, 1109 Gangxing Third Road Patentee before: QILU CELL THERAPY TECHNOLOGY CO.,LTD. |
|
CP02 | Change in the address of a patent holder |